Follow
Sophie Steeland
Sophie Steeland
Post-doctoral researcher
Verified email at irc.ugent.be
Title
Cited by
Cited by
Year
Nanobodies as therapeutics: big opportunities for small antibodies
S Steeland, RE Vandenbroucke, C Libert
Drug discovery today 21 (7), 1076-1113, 2016
4322016
A new venue of TNF targeting
S Steeland, C Libert, RE Vandenbroucke
International journal of molecular sciences 19 (5), 1442, 2018
1512018
Counteracting the effects of TNF receptor‐1 has therapeutic potential in Alzheimer's disease
S Steeland, N Gorlé, C Vandendriessche, S Balusu, M Brkic, ...
EMBO molecular medicine 10 (4), e8300, 2018
1042018
Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1
S Steeland, L Puimège, RE Vandenbroucke, F Van Hauwermeiren, ...
Journal of Biological Chemistry 290 (7), 4022-4037, 2015
802015
TNFR1 inhibition with a Nanobody protects against EAE development in mice
S Steeland, S Van Ryckeghem, G Van Imschoot, R De Rycke, ...
Scientific reports 7 (1), 13646, 2017
502017
Glucocorticoid‐induced microRNA‐511 protects against TNF by down‐regulating TNFR 1
L Puimège, F Van Hauwermeiren, S Steeland, S Van Ryckeghem, ...
EMBO molecular medicine 7 (8), 1004-1017, 2015
462015
Topical imiquimod yields systemic effects due to unintended oral uptake
L Grine, S Steeland, S Van Ryckeghem, M Ballegeer, S Lienenklaus, ...
Scientific reports 6 (1), 20134, 2016
432016
Development and validation of a small single-domain antibody that effectively inhibits matrix metalloproteinase 8
D Demeestere, E Dejonckheere, S Steeland, P Hulpiau, J Haustraete, ...
Molecular Therapy 24 (5), 890-902, 2016
262016
A study of cecal ligation and puncture-induced sepsis in tissue-specific tumor necrosis factor receptor 1-deficient mice
J Vandewalle, S Steeland, S Van Ryckeghem, M Eggermont, ...
Frontiers in Immunology 10, 493331, 2019
172019
Simultaneous inhibition of tumor necrosis factor receptor 1 and matrix metalloproteinase 8 completely protects against acute inflammation and sepsis
S Steeland, S Van Ryckeghem, J Vandewalle, M Ballegeer, ...
Critical care medicine 46 (1), e67-e75, 2018
152018
Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis
JT Guptill, JW Sleasman, S Steeland, M Sips, D Gelinas, H de Haard, ...
Autoimmunity 55 (8), 620-631, 2022
102022
Construction of novel bispecific single-domain antibodies (BiSdAbs) with potent antiangiogenic activities
X Liu, T Sun, Q Ge, J Zhu
Pharmaceutical Fronts 2 (01), e64-e76, 2020
62020
Choroid plexus tumor necrosis factor receptor 1: A new neuroinflammatory piece of the complex Alzheimer’s disease puzzle
S Steeland, RE Vandenbroucke
Neural Regeneration Research 14 (7), 1144-1147, 2019
62019
Efficient analysis of mouse genome sequences reveal many nonsense variants
S Steeland, S Timmermans, S Van Ryckeghem, P Hulpiau, Y Saeys, ...
Proceedings of the National Academy of Sciences 113 (20), 5670-5675, 2016
62016
P276 Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC+
K Musick, J Howard, G Li, T Vu, D Korobko, M Smilowski, L Liu, ...
Neuromuscular Disorders 33, S179, 2023
12023
Long-term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P10 …
J Howard, Y Li, T Vu, D Korobko, S Steeland, B Van Hoorick, J Podhorna, ...
Neurology 102 (17_supplement_1), 6334, 2024
2024
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
JF Howard Jr, V Bril, T Vu, C Karam, S Peric, JL De Bleecker, H Murai, ...
Frontiers in Neurology 14, 1284444, 2024
2024
Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis regardless of prior treatment failures
Z Siddiqi, C Rozsa, F Saccá, JL De Bleecker, J Verschuuren, S Hoffmann, ...
Journal of the Neurological Sciences 455, 2023
2023
Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017)
G Li, Y Li, T Vu, D Korobko, M Smilowski, L Liu, S Steeland, ...
Neurology 100 (17 Supplement 2), 2023
2023
Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Patients with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study (P1-5.014)
J Howard, G Li, T Vu, D Korobko, M Smilowski, L Liu, S Steeland, ...
Neurology 100 (17 Supplement 2), 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20